The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

Tinghui Duan†, Diyuan Zhou‡, Yizhou Yao‡ and Xinyu Shao§

1 Department of Medical Imaging, The Affiliated Guangji Hospital of Soochow University, Suzhou, China. 2 Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China. 3 Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China

Colorectal cancer (CRC) is one of the most frequent malignant neoplasms worldwide, and the effect of treatments is limited. Fibroblast growth factor 1 (FGF1) has been involved in a wide variety of several malignant diseases and takes part in the tumorigenesis of CRC. However, the function and mechanism of FGF1 in CRC remains elusive. In this study, the results indicated that FGF1 is elevated in CRC tissues and linked with poor prognosis (P < 0.001). In subgroup analysis of FGF1 in CRC, regardless of any clinic-factors except gender, high level FGF1 expression was associated with markedly shorter survival (P < 0.05). In addition, the expression of p-S6K1 and FGF1 was not associated in normal tissue (P = 0.781), but their expression was closely related in tumor tissue (P = 0.010). The oncogenic role of FGF1 was determined using in vitro and in vivo functional assays. FGF1 depletion inhibited the proliferation and migration of CRC cells. FGF1 was also significantly correlated with mTOR-S6K1 pathway on the gene and protein levels (P < 0.05). In conclusion, FGF1 acts as a tumor activator in CRC, and against FGF1 may provide a new visual field on treating CRC, especially for mTORC1-targeted resistant patients.

Keywords: colorectal cancer, FGF1, mTOR-S6K1 pathway, prognosis, survival

INTRODUCTION

Colorectal cancer (CRC) is the second cause of cancer death in western countries. Nearly half of the CRC patients will die from the disease which is due to distant metastasis of the primary CRC (1, 2). CRC is also one of the most prevalent malignant tumors in China, with high incidence rate and mortality. Early screening has been shown to be effective in reducing the incidence of, and mortality from CRC. A curative therapy to control the huge threat should include surgical and nonsurgical treatment. Thus, it is extremely urgent to identify effective biomarker for diagnosis and against target for treatment.

Surrounding non-neoplastic stroma acts an important role in the metastasis and invasion of tumor. Stromal cells, at the front of malignant tumor invasion, have a complicated interaction with tumor cells. Fibroblast growth factors (FGFs), called a family of heparin-binding growth factors, interact with several kinds of endothelial receptors which leads to the angiogenesis (3–5). It is
recognized that the invasion and metastasis of tumor have something to do with angiogenesis, also numerous studies show the progress of inducing angiogenesis.

FGFs are closely related to FGF receptors (FGFRs) on the target cells’ surface when their biological activities are exerted. Numerous vitro studies pay their attention on the FGF1 and FGFR1 (4, 6). FGFR1, which helps FGF-1 to exert its biological activity, is expressed by endothelial cells. Various studies measure the expression level of the FGF1 and FGFR1 in different cancers, including breast carcinoma, hepatocellular carcinoma and esophagus cancer. The expression level of FGF1 and FGFR1 in these cancers indicated that FGF1 induce the invasion and metastasis of tumor cells. In cancer cells, amplified FGF1 expression promotes the proliferation and migration ability of tumor cells (7–10). However, its expression level in CRC tissues and its expression correlated with clinical indicators and survival, have not been fully elucidated (11).

In this study, we aim to investigate the expression level of FGF1 in CRC, and detect the relationship between FGF1 expression level and diagnosis and prognosis in CRC patients in subgroup analysis. Meanwhile, we hypothesized that FGF1 regulates CRC development via mTOR–S6K1 dependent pathway, and our findings demonstrated a novel role of FGF1 in CRC and identified its potential diagnostic and therapeutic relevance.

METHODS

Human Tissue Specimens

Pairs of CRC and surrounding normal tissues were collected from 2010 to 2013. None of the patients had received radiotherapy or chemotherapy before radical surgery. Our study has been approved by the Independent Ethics Committee of the Affiliated Suzhou Hospital of Nanjing Medical University and the First Affiliated Hospital of Soochow University (IRB approval number, 2020076), and all patients wrote informed consent.

Tissue Specimens and Immunohistochemistry

Tissues were fixed with 10% formalin, embedded in paraffin, and cut into 5μm-thick sections. Then, they were detected via IHC according to the protocol as our previous study (12, 13). a) The sections were dewaxed in xylene twice and rehydrated using ethanol (95%, 90%, 75%) and distilled water. b) Submerged the sections in sodium citrate antigen-repair buffer and oven heating the buffer to 92-98°C for 15min, and then cool down to room temperature for 2-3 times. Wash with PBS for 2-3 times. c) Block the endogenous peroxidase with 3% hydrogen peroxide for 10-15min, and then washed with PBS for 2-3 times. d) The sections were incubated with 5% goat serum for 30 min, then the goat serum was removed and antibodies were added overnight at 4°C. e) The slides were washed with PBS for 3 times/10 min and incubated with secondary antibodies for 30 min, and then washed with PBS for 3 times/10 min. f) Finally, the sections were colored with diaminobenzidine (DAB) and stained nuclei with hematoxylin. g) Seal the sections with neutral resins.

A tissue staining kit (Zhongshan Biotechnology, China) was used and tissue sections were incubated overnight with 1:200 diluted polyclonal anti-human FGF1 (BOSTER, China) or anti-human p-S6K1 (Cell Signaling Technology, USA) at 4°C. The percentage of positively stained cells was scored as follows: score 0 represents 0-5%; score 1 represents 6-25%; score 2 represents 26-50%; score 3 represents 51-75%; score 4 represents >75%. The staining intensity was scored as 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). The percentage score was multiplied by intensity score to show the selected region. The final score was the average of five random selected regions. It graded as follows: − (0), + (1-4), ++ (5-8) and +++ (9-12). Samples with final scores ++ or +++ were graded positive, and - or + as negative. The tumor budding was quantified according the criteria of International Tumor Budding Consensus Conference (ITBCC) (14). The invasion front and hot-spot areas were identified in low-power view, then single cell and clusters of up to 4 cells at the invasive margin of CRC were counted with 20 x objective lens (15, 16).

Bioinformatics Analysis

Relevant gene expression datasets were analyzed via the Oncomine (https://www.oncomine.org) and GEPIA (Gene Expression Profiling Interactive Analysis, http://gepia.cancer-pku.cn) platform.

Cell Culture and Transfection

CRC cell lines were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai, China), and were cultured in RPMI 1640 medium (Hyclone, USA) supplemented with 10% fetal bovine serum (Gibco, USA), penicillin G sodium (100U/ml) and streptomycin (100μg/ml) at 37°C under 5% CO2. The cells were grown till 70% confluency, and transfected with human FGF1 shRNA (5'-CCGGCCCTCTGACAGAAGGTTATCTTTTC AAGAGGATAACTTCTCGTCAAGGGTTTGT-3') according to the manufacturer’s instructions. The transfected cells were selected using 500μg/ml G418 (Roche, Switzerland) for 3-4 weeks, and clones with a stable knockdown of FGF1 were selected for further experiments.

RNA Isolation and Quantitative Real-Time PCR

Total RNA was extracted from the tissues or cells using TRIzol reagent (Invitrogen, Life Technologies, USA) according to the manufacturer’s protocol. Following DNase I (Thermo Fisher Scientific, USA) treatment to remove genomic DNA, 1μg RNA was reverse transcribed using a RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, USA). The qRT-PCR was performed using Power SYBR® Green PCR Master Mix (ABI, USA) on the 7500 real time PCR system (ABI, USA) according to the manufacturer’s instructions. The following primers were used: FGF1 forward (5'-GGTGATGGGACA AGGGACAG-3’) and reverse (5’-GGCCAGGAGAAAC AAGAT-3’); β-actin forward (5’-CCACACTTGCCCCATCT ACG-3’) and reverse (5’-AGGATCTTCATGAGGTAGT
CAGTCAG-3’). Fold changes were calculated relative to β-actin (internal control) using the 2−ΔΔCt method.

**Western Blotting**
The extracted proteins were separated by SDS-PAGE and transferred onto PVDF membranes (Millipore, USA). After blocking with 5% non-fat milk for 1h, the membranes were probed overnight with FGF1 (1:1000, BOSTER, China), p-mTOR (1:1000, Cell Signaling Technology, USA), mTOR (1:1000, Bioss, China), p-S6K1 (1:1000, Cell Signaling Technology, USA), and S6K1 (1:1000, Bioss, China) and β-Actin (1:5000, BOSTER, China) antibodies at 4°C with gentle shaking, followed by horseradish peroxidase-conjugated secondary antibodies. The protein bands were visualized by chemiluminescence and quantified by ImageJ (NIH, USA).

**Colony Formation Assay**
The suitably transfected cells were seeded in 6-well plates at the density of 1000 cells/well, and cultured for 10 days before being fixed and stained with 0.1% crystal violet. The colonies with more than 100 cells were counted at 40x magnification under an optical microscope (Nikon, Japan).

**Transwell Assay**
Cell migration ability was assessed using Transwell inserts (pore size 8µm; Corning, USA). The cells were seeded into the upper chambers of the inserts at the density of 10,000 cells/200µl in serum-free RPMI 1640 medium, and the lower chambers were filled with 800µl complete medium per well. After incubating for 12h at 37°C, the cells remaining on the upper surface of the membrane were removed using a cotton swab. The filters were then fixed with 4% paraformaldehyde, and the cells on the lower surface were stained with 0.1% crystal violet and counted in 5 random fields per sample.

**Wound Healing Assay**
Wound healing assay was also adopted to test the migration ability of colon cancer cells. Cells were plated in 6-well plates, when cell confluence reached approximately 100%, the old medium was removed and the monolayer was wounded by scratching with a 100µl sterile pipette tip lengthwise along the chamber, then cells were washed three times with PBS and cultured with serum-free medium at 37°C. Images of cells migrating into the wound were recorded at 0h and 24h using an inverted microscope. Wound width was measured using OpenLab (Agilent, USA). The experiments were repeated three times.

**Subcutaneous Xenograft Establishment**
SPF male BALB/c nude mice (4weeks old and weighing 16-18g) were purchased from Shanghai SLRC laboratory Animal Co. Ltd. (Shanghai, China). The mice were randomly divided into the FGF1 knock down (KD) and negative control (NC) groups (n = 5 per group), and accordingly injected subcutaneously with 5×10⁶ FGF1-KD or NC-shRNA HCT116 into the right dorsal flank on day 0. All animal experiments were approved by the Animal Ethics Committee of the Affiliated Suzhou Hospital of Nanjing Medical University (Suzhou, China).

**Statistical Analysis**
All methods were carried out in accordance with relevant guidelines and regulations. All patients were followed up by personal or telephonic interviews for 60 months, and the time point was set as the date of CRC-related death or 60 months after surgery. Self-developed R program (version 3.6.1 for Windows, http://cran.r-project.org/) was used for Cluster analysis and Nomogram analysis. SPSS 22.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 8 (San Diego, CA) were also used to perform statistical analysis. All data were presented as mean ± SD of three independent experiments. The Student’s t-test (unpaired, two-tailed) or one-way ANOVA were used to compare means between two groups. IHC results were analyzed by Chi-squared or Fisher’s exact tests. P < 0.05 was considered statistically significant.

**RESULTS**

**FGF1 Is Elevated in CRC Tissues and Linked With Poor Prognosis**
To assess the FGF1 expression level in colorectal normal tissue and paired CRC tissue, we searched the findings of Skrzypczak et al, which revealed FGF1 was aberrant active in CRC tissue (Figure 1A). However, the outcome was not consistent with the findings of pooled analysis of FGF1 expression of CRC and normal tissues across 16 datasets searched via Oncomine platform (Figure 1B). To confirm the inconsistent result, we detected the FGF1 expression in 135 CRC and paired normal colorectal tissues via IHC. The FGF1 protein was reduced in normal colon tissues, and significantly higher in the CRC tissues (P < 0.001, Figures 1C, D and Table 1).

Moreover, FGF1 expression was significantly associated with lymph node metastasis (P = 0.003), tumor budding degree (P = 0.002) and TNM stage (P = 0.001, Table 2), while no correlation was observed with other clinicopathological variables such as age, gender, tumor size, the depth of invasion, degree of differentiation, venous invasion and neural invasion (P > 0.05, Table 2). In further univariate analysis, it revealed that depth of invasion, degree of differentiation, lymph node metastasis, venous invasion, neural invasion, TNM stage and FGF1 expression (P < 0.001, Table 3) acted as an independent prognostic factor for the survival of CRC patients. Meanwhile, FGF1 expression level also played a significant role in multivariate analysis (P < 0.001, Table 3). To demarcated the patients according to FGF1 expression levels, we found the reduced FGF1 expression promoted prognosis in TCGA dataset searched by GEPIA platform (Figure 1E) and checked in 135 CRC tissues (Figure 1F).

**Subgroup Analysis of FGF1 in CRC**
After the analysis of FGF1 expression in CRC and normal tissues, and expression effect on prognosis, we further investigated the
The subgroup influence of FGF1 exerts in CRC. 135 CRC tissues were assessed according to the outcome of IHC test (Figure 2A). FGF1 levels was significantly increased in patients with tumor–node–metastasis (TNM) stage III-IV compared with I-II (Figure 2B). Furthermore, FGF1 expression showed similar elevated trend in CRC tissues with lymph node metastasis compared with those without in situ (Figure 2C). No matter in TNM stage I-II or III-IV subgroup, amplified FGF1 expression still indicated the poor prognosis (Figures 2D, E).

In order to better reveal the influence of FGF1 level on the prognosis of CRC patients, we conducted subgroup analysis on prognosis of patients based on various clinicopathological characteristics. The outcome suggested that regardless of age, gender, tumor size, depth of invasion, lymph node metastasis, degree of differentiation, venous invasion, neural invasion and TNM stage, high level FGF1 expression was associated with markedly shorter survival (Figure 3).

**The Nomogram Predicts the Prognosis of the CRC Patients**

Age, gender, neural invasion, vascular invasion, tumor size, differentiation, T stage, N stage, M stage and FGF1 expression were used to estimate 3- and 5- year OS (Figure 4). The nomogram gave every prognostic variable a score on the point scale and we found a score associated with each prognostic factor on the nomogram point scale and calculated the total score (Figure 4). And, FGF1 acted as an important role in the prognosis of CRC patients.

**Association Between FGF1 and p-S6K1 Expression**

As reported, studies suggested that FGF1 may promote proliferation and metastasis of tumor cells by regulating the AKT-mTOR-S6K1 signaling pathway in a variety of tumors. TCGA dataset analysis by GEPIA platform showed that the expression of FGF1 in colorectal cancer tissues was positively correlated with S6K1 (Figure 5A). To verify the relationship between FGF1 and the AKT-mTOR-S6K1 axis in CRC, firstly,
we investigated the expression of p-S6K1 in 135 samples in protein level via IHC (Figure 5B). Compared to normal tissues, the expression of p-S6K1 in CRC tissue was significantly elevated (Figure 5C). Then, we examined the correlation between FGF1 and p-S6K1 expression. The expression of p-S6K1 and FGF1 was not associated in normal tissue, but their expression was closely related in tumor tissue (Figures 5D, E).

In subgroup analysis according to the TNM stage, their expression was no obvious association in tissues at TNM stage I-II (Figure 5F). Whereas, in the TNM stage III-IV group, p-S6K1 was closely linked to FGF1 (Figure 5G). Therefore, the expression of FGF1 and p-S6K1 increased aberrantly in a large proportion of CRC specimens. Meanwhile, p-S6K1 expression was associated with FGF1 expression obviously in advanced CRC. Moreover, PCoA cluster analysis was performed based on the IHC scores of FGF1 and p-sk61. The difference between tumor tissue and normal tissue can be clearly distinguished on the PC1 axis (Figure 5H).

To gain further mechanistic insights, we examined the knockdown effect of FGF1 in colorectal cancer cells firstly. Then, the p-mTOR and p-S6K1 expression in CRC cells transfected with FGF1-shRNA was analyzed. It indicated that inhibiting FGF1 downregulated mTOR-S6K1 pathway (Figures 6A, B).

Ectopic FGF1 Promotes Proliferation and Migration Ability of CRC Cells

mTOR-S6K1 pathway is closely related to the proliferation and migration of cancer cells. Due to the close regulatory relationship between FGF1 and mTOR-S6K1 pathway, we investigated the biological role of FGF1 on the proliferation and migration ability of CRC cells. Compared to the negative controls, the colony-formation ability of FGF1-KD cells was significantly reduced (Figure 7A). Consistent with this, the FGF1-KD cells also showed decreased migration ability in transwell assays (Figure 7B), and wound healing assays (Figures 7C, D). Taken together, the ectopic expression of FGF1 promotes tumorigenesis of CRC cells in vitro.

FGF1 Enhances Colorectal Tumorigenesis In Vivo

The role of FGF1 in CRC tumor growth was analyzed by establishing an in vivo xenograft model using wild-type and FGF1-KD HCT116 cells. Depletion of FGF1 alleviated the nutritional status of mice to a certain extent (Figure 8A), and significantly inhibited the proliferative capacity of the CRC cells, which was manifested as reduced tumor size (Figures 8B, C) and weight (Figure 8D) compared to control group. Then, we evaluated the difference of mice weight after tumor removal,

### Table 2: Relationship between FGF1 and clinic-pathological factors in CRC patients.

| Variables                          | FGF1          |          |          |          |
|------------------------------------|---------------|----------|----------|----------|
|                                    | Negative     | Positive | P value  |          |
| Age (years) ≤60                    | 19            | 38       | 0.100    |          |
| Age (years) >60                    | 37            | 41       |          |          |
| Gender Male                        | 32            | 45       | 0.983    |          |
| Gender Female                      | 24            | 34       |          |          |
| Tumor size (cm) <5                 | 27            | 32       | 0.374    |          |
| Tumor size (cm) ≥5                 | 29            | 47       |          |          |
| Depth of tumor invasion T1-2       | 14            | 11       | 0.103    |          |
| Depth of tumor invasion T3-4       | 42            | 68       |          |          |
| Lymph node metastasis No           | 36            | 30       | 0.003*   |          |
| Lymph node metastasis Yes          | 20            | 49       |          |          |
| Degree of differentiation Well     | 48            | 63       | 0.372    |          |
| Degree of differentiation Poor     | 8             | 16       |          |          |
| Venous invasion Negative           | 44            | 52       | 0.107    |          |
| Venous invasion Positive           | 12            | 27       |          |          |
| Neural invasion Negative           | 42            | 49       | 0.113    |          |
| Neural invasion Positive           | 14            | 30       |          |          |
| Tumor budding degree Low           | 36            | 29       | 0.002*   |          |
| Tumor budding degree High          | 20            | 50       |          |          |
| TNM staging I-II                   | 36            | 28       | 0.001*   |          |
| TNM staging III-IV                 | 20            | 51       |          |          |

*P < 0.05.

### Table 3: Results of univariate and multivariate analyses of underwent gastrectomy patients’ survival by Cox’s proportional hazard model.

| Varieties                          | n          | HR 95% CI          | P    | HR 95% CI          | P    |
|------------------------------------|------------|--------------------|------|--------------------|------|
|                                    | Univariate | Multivariate       |      | Univariate         |      |
|                                    |            |                    |      |                    |      |
| Age (≤60 or >60 years)             | 57/78      | 1.084 0.698-1.687  | 0.722| 0.350 0.154-0.794  | 0.012*|
| Gender (Male/Female)               | 77/58      | 0.876 0.561-1.386  | 0.559| 9.250 1.892-9.000  | 0.006*|
| Tumor size (≤5 or >5 cm)           | 59/76      | 0.654 0.418-1.023  | 0.063| 0.629 0.365-1.118  | 0.117|
| Depth of tumor invasion T1-2       | 25/110     | 0.223 0.102-0.487  | <0.001*| 0.618 0.374-1.022  | 0.061|
| Lymph node metastasis negative     | 66/69      | 0.179 0.108-0.298  | <0.001*| 0.880 0.541-1.431  | 0.607|
| Degree of differentiation well      | 111/24     | 0.461 0.270-0.787  | 0.005*| 0.029 0.006-0.149  | <0.001*|
| Venous invasion negative/poor       | 96/39      | 0.374 0.230-0.595  | <0.001*| 0.204 0.113-0.371  | <0.001*|
| Neural invasion negative/poor       | 91/44      | 0.544 0.346-0.856  | 0.008*| 9.250 1.892-9.000  | 0.006*|
| TNM staging I-II                   | 64/71      | 0.157 0.093-0.264  | <0.001*| 0.204 0.113-0.371  | <0.001*|
| FGF1 expression negative/poor       | 56/79      | 0.188 0.107-0.332  | <0.001*| 9.250 1.892-9.000  | 0.006*|

*P < 0.05.
FIGURE 2 | Effect of FGF1 on survival. (A) IHC images showing in situ FGF1 expression in CRC tissues (scale bar = 100μm). Negative (a), Weak (b), Moderate (c), Strong (d). (B) IHC scores of FGF1 in TNM stage I-II vs stage III-IV. (C) IHC scores of FGF1 in nLNM vs LNM. (D, E) OS of FGF1(+) and FGF1(-) CRC patients with TNM staging (D) I-II and (E) III-IV. nLNM, no lymph node metastasis; LNM, lymph node metastasis. **P < 0.01.

FIGURE 3 | Subgroup analysis for the influence factor of survival duration of CRC patients according to FGF1 expression. *P < 0.05.
and the weight of mice in FGF1-KD group was still superior to negative controls (Figure 8E).

Furthermore, FGF1 mRNA levels in situ were markedly affected the weight of Subcutaneous tumor, and showed significant statistical correlation (Figure 8F). We next performed a cluster analysis to consider the combined effects of tumor volume and FGF1 expression level (Figure 8G). 80% of the FGF1-KD group mice were in Cluster 1, and 100% of the NC and 20% of the FGF1-KD group mice were in Cluster 2 (Figure 8H). It suggests that there is a significant difference between FGF1-KD and negative control CRC cells in vivo.

**DISCUSSION**

In recent years, at least 22 different FGFs have been identified, ranging from nematodes and fruit flies to mice and humans (17, 18). FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. As an important member of the FGFs family, FGF1 functions as a modifier of endothelial cell migration and proliferation, as well as an angiogenic factor (5, 7). It acts as a mitogen for a variety of mesoderm- and neuroectoderm-derived cells in vitro, thus is thought to be involved in organogenesis.

As reported, FGF2 and FGF20 are the major FGFs involved in embryogenesis and colorectal tissue regeneration. However, the expression level and role of FGF1 in colorectal cancer remain unclear. In this study, FGF1 expression was significantly higher in colorectal cancer than in normal tissues by detecting 135 normal and paired CRC tissues. Regarding the detection of FGF1 expression level, our results were consistent with Skrzypczak’s (19). However, a pooled analysis of 16 studies included by the Oncomine platform do not support the result that expression levels of FGF1 is higher in CRC than in normal tissues (20, 21). Therefore, more studies are needed to clarify and support this conclusion. Meanwhile, elevated FGF1 expression level in tumor tissues was associated with poor prognosis. This result is consistent with TCGA database outcome. Studies in ovarian cancer, breast cancer and lung cancer suggest that FGF1 expression levels in tumor tissues are closely related to prognosis (4, 7–10). However, the prognostic role of FGF1 in CRC patients is still lacking.

In addition to demonstrating that FGF1 predicts a poor prognosis in CRC, we also performed a subgroup analysis to further reveal the association between FGF1 and survival of CRC patients in different subgroups. Interestingly, we found that high expression of FGF1 predicted poor prognosis no matter at different TNM stages, lymph node metastasis, degree of differentiation, and depth of tissue infiltration etc. However, we found different prognostic effects of FGF1 in nongender-specific
FIGURE 5 | The relationship between FGF1 and p-S6K1. Nomograms to predict survival of CRC patients. (A) Correlation analysis of FGF1 and S6K1 at gene level in CRC tissues from TCGA datasets by GEPIA platform. (B) Representative IHC images showing in situ p-S6K1 expression in CRC and normal tissues (scale bar = 100 μm). (C) IHC scores of p-S6K1 in CRC vs normal tissues. (D–G) Correlation between FGF1 and p-S6K1 at protein level in (D) CRC tissue, (E) normal tissue, (F) TNM stage I-II tissue and (G) TNM stage III-IV tissue. (H) Stratification of 135 pairs of CRC and normal tissues into cluster 1 and cluster 2 according to FGF1 and p-S6K1 IHC scores. ***P < 0.001.

FIGURE 6 | FGF1 regulates CRC cell growth in an mTOR-S6K1 pathway dependent manner. (A) Immunoblot showing FGF1, p-mTOR, mTOR, p-S6K1 and S6K1, β-Actin protein levels in CRC cells transfected with FGF1-shRNA. (B) Immunoblot result of FGF1/β-Actin, p-mTOR/mTOR and p-S6K1/S6K1 were semi-quantified by ImageJ. Data are presented as mean ± SD. NC, negative control; KD, FGF1-shRNA. *P < 0.05; **P < 0.01.
subgroups. FGF1 was associated with survival in the female subgroup, but not in the male subgroup. It indicates FGF1 may be more effective in predicting survival in female patients. However, this conclusion has its limitation, which may be due to the low number of positive FGF1 detected in CRC tissues in male patients. Therefore, the analysis may not be accurate (22, 23). And, a further increase in male cases is needed to provide reliable analysis.

FGF1 is involved in cell proliferation, survival, migration, invasion, differentiation, and angiogenesis. It is recognized that the invasion and metastasis of tumor have something to do with angiogenesis. As FGF1 was found to be correlated with lymph node metastases. Study suggests that the angiogenesis intensity in CRC is higher in early-stages of the tumoral proliferation. However, it is not an increasing process, having rather an oscillating character (24). High angiogenic activity in early tumor tissues may be an important factor in promoting the gradual increase of FGF1 expression. Thus, it is easily hijacked by cancer cells and shows oncogenic roles in many cancers (17, 18). The phosphorylation of FGFRs by FGFs initiates biological effects through activation of different signaling pathways including the PI3K-AKT-mTOR pathway. However, the association of FGF1 with PI3K-AKT-mTOR pathway in CRC is unclarified (7, 25, 26). TCGA dataset analysis revealed that FGF1 links with SK61, which is the downstream target of mTOR. IHC results showed no correlation between FGF1 and

![FIGURE 7 | FGF1 promotes proliferation and migration ability of CRC cells. (A, B) Colony formation capacity (A) and migration rates (B) of FGF1-KD CRC cells. CRC, colorectal cancer. (C) Wound healing assays were carried out at 24h after transfection in 6-well plates. The gap width was measured using Open Lab software. (D) The wound rate was calculated and displayed graphically according to the measured results by Open Lab software. NC, negative control; KD, FGF1-shRNA. Data are presented as mean ± SD (n=3). Ns, no significance, *P < 0.05.](image)
phosphorylated S6K1 in normal colorectal tissues, but a positive correlation in CRC tissues. Furthermore, in a subgroup analysis based on TNM stage, we found no correlation between FGF1 and p-S6K1 in early CRC, while FGF1 was closely associated with p-S6K1 in advanced CRC. This evidence enhanced that FGF1 expression levels and their association with the AKT-mTOR signaling pathway become increasingly tight as tumors develop. And, FGF1 may act as an excellent biomarker to predict the process of tumorigenesis (7).

PI3K-Akt-mTOR is an important metabolic signaling pathway (27, 28), which is aberrant expression in a variety of tumor cells (29–32). Studies have shown that the abnormal activation of mTORC1 complex promotes the proliferation and migration ability of CRC cells (33–35). However, FGF1 is closely related to the activation level of mTORC1, the potential regulatory mechanism between FGF1 and mTORC1 has not been clarified in a variety of digestive tract tumors. To further clarify the regulatory relationship between FGF1 and mTOR related signaling pathways, we knocked down the expression of FGF1, analyzed the expression alteration of mTOR and its downstream targets, and evaluated the proliferation and migration ability of tumor cells in vitro and in vivo. The results indicated that knockdown of FGF1 negatively regulated the phosphorylation levels of mTOR and S6K1. Meanwhile, down-regulation of FGF1 expression can effectively inhibit the proliferation and migration ability of colorectal cancer cells in vitro. In vivo, down-regulation of FGF1 expression delayed the occurrence and progression of tumors and effectively improved the nutritional status of tumor-bearing mice.

In sum, there are still few studies on FGF1 in CRC, and its role and underlying mechanism have not been fully elucidated. The comprehensive understanding of FGF1 structure and function,
as well as elucidation of the specific FGF1 inhibitor interactions, and combined with further study of the effect of FGF1 in CRC may promote new strategies for the treatment of CRC.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of the Affiliated Suzhou Hospital of Nanjing Medical University. The studies involving non-human participants were reviewed and approved by the Animal Ethics Committee of the Affiliated Suzhou Hospital of Nanjing Medical University. The animal study was reviewed and approved by the Animal Ethics Committee of the Affiliated Suzhou Hospital of Nanjing Medical University.

REFERENCES

1. Siegel R, Desantis C and Jemal A. Colorectal Cancer Statistics, 2014. CA Cancer J Clin (2014) 64(2):104–17. doi: 10.3332/caac.21220
2. Siegel RL, Miller KD and Jemal A. Cancer Statistics, 2019. CA Cancer J Clin (2019) 69(1):7–34. doi: 10.3332/caac.21551
3. Ronca R, Giaconi M, Rusnati M and Presta M. The Potential of Fibroblast Growth Factor/Fibroblast Growth Factor Receptor Signaling as a Therapeutic Target in Tumor Angiogenesis. Expert Opin Ther Targets (2015) 19(10):1361–77. doi: 10.1517/14728222.2015.1062475
4. Slattery ML, John EM, Stern MC, Lundgreen A, Giuliano AR, et al. Associations With Growth Factor Genes (FGF1, FGF2, PDGFB, FGF2, NRG2, EGF, ERBB2) With Breast Cancer Risk and Survival: The Breast Health Disparities Study. Breast Cancer Res Treat (2013) 140(3):587–601. doi: 10.1007/s10549-013-2644-5
5. Szlachcic A, Sochacka M, Cyrek A, Opalinski L, Krowarsch D, Otlewski J, et al. Low Stability of Integrin-Binding Deficient Mutant of FGF1 Restricts Its Biological Activity. Cells (2019) 8(6). doi: 10.3390/cells0800899
6. Ribatti D, Vacca A, Rusnati M and Presta M. The Discovery of Basic Fibroblast Growth Factor/Fibroblast Growth Factor-2 and Its Role in Haematological Malignancies. Cytokine Growth Factor Rev (2007) 18(3-4):327–34. doi: 10.1016/j.cytogfr.2007.04.011
7. Wu D, Yang B, Chen J, Xiong H, Li Y, Pan Z, et al. Upregulation of Long Non-Coding RNA RAB1A-2 Induces FGFI Expression Worsening Lung Cancer Prognosis. Cancer Lett (2018) 438:116–25. doi: 10.1016/j.canlet.2018.09.016
8. Liu P, Zhang R, Yu W, Ye Y, Cheng Y, Han L, et al. FGF1 and IGF1-Conditioned 3D Culture System Promoted the Amplification and Cancer Stemness of Lung Cancer Cells. Biomaterials (2017) 149:63–76. doi: 10.1016/j.biomaterials.2017.09.030
9. Chen J, Zhou Z, Yao Y, Dai J, Zhou D, Wang L and Zhang QQ. Dipalmitoylphosphatidic Acid Inhibits Breast Cancer Growth by Suppressing Angiogenesis via Inhibition of the CUX1/FGF1/HGF Signalling Pathway. J Cell Mol Med (2018) 22(10):4760–70. doi: 10.1111/jcmm.13727
10. King ML, Lindberg ME, Stodden GR, Okuda H, Ebers SD, Johnson A, et al. WNT7A/Beta-Catenin Signaling Induces FGF1 and Influences Sensitivity to Niclosamide in Ovarian Cancer. Oncogene (2015) 34(26):3452–62. doi: 10.1038/onc.2014.277

AUTHOR CONTRIBUTIONS

TD and XS carried out the literature search, experiments and data acquisition, participated in the study design, and drafted the manuscript. TD, DZ, YY, and XS collected the data, participated in the study design, and helped draft the manuscript. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We gratefully acknowledge the valuable cooperation and guidance of the two pathological colleagues, Zheng Zhi (The Affiliated Suzhou Hospital of Nanjing Medical University) and Xiuming Li (The First Affiliated Hospital of Soochow University), in assessing the IHC results. Nanjing Medical University Science and Technology Development Fund (NMUB2018231), Suzhou Special Project of Diagnosis and Treatment for key Clinical Disease (LCZX201814) and Suzhou Science, Technology Development Project (SYSD2018144) and Project of Youth Foundation in Science and Education of Department of Public Health of Suzhou (KJXW2018001).

11. Sato T, Oshima T, Yoshikura K, Yamamoto N, Yamada R, Nagano Y, et al. Overexpression of the Fibroblast Growth Factor Receptor-1 Gene Correlates With Liver Metastasis in Colorectal Cancer. Oncol Rep (2009) 21(1):211–6. doi: 10.3892/or_00000210
12. Yao Y, Yang X, Sun L, Sun S, Huang X, Zhou D, et al. Fatty Acid 2-Hydroxylation Inhibits Tumor Growth and Increases Sensitivity to Cisplatin in Gastric Cancer. EBioMedicine (2019) 41:256–67. doi: 10.1016/j.ebiom.2019.01.066
13. Shao X, Kuai X, Pang Z, Zhang L, Wu L, Xu L and Zhou C. Correlation of Glit and HER2 Expression in Gastric Cancer: Identification of Novel Target. Sci Rep (2018) 8(1):397. doi: 10.1038/s41598-017-17435-6
14. Lugli A, Kirsch R, Aijo Y, Bosman F, Cathomas G, Dawson G, et al. Recommendations for Reporting Tumor Budding in Colorectal Cancer Based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol (2017) 30(9):1299–311. doi: 10.1038/modpathol.2017.46
15. Ueno H, Kajiwara Y, Shimazaki H, Shiento E, Hashiguchi Y, Nakashiki K, et al. New Criteria for Histologic Grading of Colorectal Cancer. Am J Surg Pathol (2012) 36(2):193–201. doi: 10.1016/j.apsup.2012.03.025
16. Banias L, Gurzu S, Kovacs Z, Bara T, Bara TJr., Jung I. Nuclear Maspin Expression: A Biomarker for Budding Assessment in Colorectal Cancer Specimens. Pathol Res Pract (2017) 213(9):1227–30. doi: 10.1016/j.jprp.2017.07.025
17. Weng M, Chen Z, Xiao Q, Li R, Chen Z. A Review of FGFI Signaling in Palate Development. BioMed Pharmacother (2018) 103:240–7. doi: 10.1016/j.biopha.2018.04.026
18. Zhao D, Lu Y, Yang C, Zhou X and Xu Z. Activation of FGFI Receptor Signaling Promotes Invasion of Non-Small-Cell Lung Cancer. Tumour Biol (2015) 36(5):3637–42. doi: 10.1007/s13277-014-3001-y
19. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosi D, et al. Modeling Oncogenic Signaling in Colon Tumors by Multidirectional Analyses of Microarray Data Directed for Maximization of Analytical Reliability. PloS One (2010) 5(10). doi: 10.1371/journal.pone.0013091
20. Wang T, Liu H, Pei L, Wang K, Song C, Wang P, et al. Screening of Tumor-Associated Antigens Based on Oncomine Database and Evaluation of Diagnostic Value of Autoantibodies in Lung Cancer. Clin Immunol (2020) 210:108262. doi: 10.1016/j.clim.2019.108262
21. Liu W, Ouyang S, Zhou Z, Wang M, Wang T, Qi Y, et al. Identification of Genes Associated With Cancer Progression and Prognosis in Lung Adenocarcinoma: Analyses Based on Microarray From Oncomine and the
Cancer Genome Atlas Databases. *Mol Genet Genomic Med* (2019) 7(2): e00528. doi: 10.1002/mgg3.528

22. Martinez-Camblo P, Mackenzie T, Staiger DO, Goodney PP, O’Malley AJ. Adjusting for Bias Introduced by Instrumental Variable Estimation in the Cox Proportional Hazards Model. *Biostatistics* (2019) 20(1):80–96. doi: 10.1093/biostatistics/kxx062

23. Yang X, Zhou Y. Improve Efficiency and Reduce Bias of Cox Regression Models for Two-Stage Randomization Designs Using Auxiliary Covariates. *Stat Med* (2017) 36(11):1683–95. doi: 10.1002/sim.7252

24. Gurzu S, Jung J, Azamfrei L, Cimpean AM, Szentirmay Z. The Angiogenesis in Colorectal Carcinomas With and Without Lymph Node Metastases. *Rom J Morphol Embryol* (2008) 49(2):149–52. doi: 10.1071/RD08085

25. Lam NT, Tandon I, Balachandran K. The Role of Fibroblast Growth Factor 1 and 2 on the Pathological Behavior of Valve Interstitial Cells in a Three-Dimensional Mechanically-Conditioned Model. *J Biol Eng* (2019) 13:45. doi: 10.1186/s13036-019-0168-1

26. Manuvakhova M, Thottassery JV, Hays S, Qu Z, Rentz SS, Westbrook L and Kern FG. Expression of the SNT-1/FRS2 Phosphotyrosine Binding Domain Inhibits Activation of MAP Kinase and PI3-Kinase Pathways and Antiestrogen Resistant Growth Induced by FGF-1 in Human Breast Carcinoma Cells. *Oncogene* (2006) 25(44):6003–14. doi: 10.1038/sj.onc.1209592

27. Dreschers S, Ohl K, Mollmann J, Tenbrock K, Orlikowsky TW. Leucine Reconstitutes Phagocytosis-Induced Cell Death in E. Coli-Infected Neonatal Monocytes-Effects on Energy Metabolism and mTOR Signaling. *Int J Mol Sci* (2021) 22(8). doi: 10.3390/ijms22084271

28. Ding Y, Yu J, Chen X, Wang S, Tu Z, Shen G, et al. Dose-Dependent Carbon-Dot-Induced ROS Promote Uveal Melanoma Cell Tumorigenicity via Activation of mTOR Signaling and Glutamine Metabolism. *Adv Sci (Weinh)* (2021) 8(8):2002404. doi: 10.1002/advs.202002404

29. Murugan AK. mTOR: Role in Cancer, Metastasis and Drug Resistance. *Semin Cancer Biol* (2019) 59:92–111. doi: 10.1016/j.semcancer.2019.07.003

30. Yang M, Huang Q, Li C, Jiang Z, Sun J, Wang Z, et al. TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer. *Front Immunol* (2021) 12:6475-40. doi: 10.3389/fimmu.2021.647540

31. Wang Z, Goto Y, Allevato MM, Wu VH, Saddawi-Konefla R, Gilardi M, et al. Disruption of the HER3-Pi3K-mTOR Oncogenic Signaling Axis and PI-1 Blockade as a Multimodal Precision Immunotherapy in Head and Neck Cancer. *Nat Commun* (2021) 12(1):2338. doi: 10.1038/s41467-021-22619-w

32. Jiao Y, Xiong Y, He L, Yang Z, Yuan H, Liu D, et al. Dioscorea Deltoidea Leaf Extract (DDLE) Targets PI3K/AKT/mTOR Pathway and Inhibits Ovarian Cancer Cell Growth. *Doki Biochem Biophys* (2021) 497(1):144–50. doi: 10.1134/S1607672921020058

33. Yu S, Hu Q, Fan K, Yang C, Gao Y. CSNK2B Contributes to Colorectal Cancer Cell Proliferation by Activating the mTOR Signaling. *J Cell Commun Signal* (2021) (15):383–92. doi: 10.1007/s12079-021-00619-1

34. Zhang T, Ji D, Wang P, Liang D, Jin L, Shi H, et al. The Atypical Protein Kinase RIOK3 Contributes to Glioma Cell Proliferation/Survival, Migration/Invasion and the AKT/mTOR Signaling Pathway. *Cancer Lett* (2018) 415:151–63. doi: 10.1016/j.canlet.2017.12.010

35. Yao Y, Zhou D, Shi D, Zhang H, Zhan S, Shao X, et al. GLI1 Overexpression Promotes Gastric Cancer Cell Proliferation and Migration and Induces Drug Resistance by Combining With the AKT-mTOR Pathway. *BioMed Pharmacother* (2019) 111:993–1004. doi: 10.1016/j.biopha.2019.01.018

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Duan, Zhou, Yao and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.